Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension

摘要

For several decades, patients with acute symptomatic VTE including DVT and/or pulmonary embolism (PE) generally were treated with anticoagulants for only 3?months. In the 1990s, the continued high risk of recurrent VTE in patients who had stopped the 3-month course of anticoagulant therapy was recognized and documented clearly.